BioCentury | Oct 22, 2015
Distillery Therapeutics

Therapeutics: Undecaprenyl diphosphate synthase (uppS)

...inhibited bacterial growth with a minimum inhibitory concentration (MIC) of 8 μg/mL and inhibited bacterial uppS...
...ESR1) , in registration to treat hypogonadism and Phase II testing to treat diabetes. TARGET/MARKER/PATHWAY: Undecaprenyl diphosphate synthase (uppS)...
BioCentury | Feb 27, 2014
Cover Story

AMPlifying targets

Although small- and medium-sized biotechs are absent from the NIH 's new Accelerating Medicines Partnership with industry and not-for-profit organizations, consortium leaders expect that making results publicly available on their search for new targets and...
BioCentury | Nov 21, 2013
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Uridine phosphorylase 1 (UPP1) Cell culture studies identified UPP1 inhibitors that could be useful for improving the efficacy of 5-fluorouracil...
BioCentury | Jan 17, 2013
Distillery Therapeutics

Indication: Infectious disease

...contact information Infectious disease Bacterial infection Undecaprenyl diphosphate synthase (uppS) In vitro and mouse studies identified inhibitors of uppS...
...help treat bacterial infection. Crystallographic and in vitro studies identified a lead compound that inhibited uppS...
BioCentury | Apr 23, 2007
Tools & Techniques

Upstaging Velcade

When Millennium Pharmaceuticals Inc. began working on the first proteasome inhibitor to reach the market, Velcade bortezomib, one of the potential issues was that the presence of proteasomes in all cells and the proteasome's broad...
Items per page:
1 - 5 of 5